Published on 22 Oct 2021 on Zacks via Yahoo Finance
Salarius (SLRX) Reports Q3 Loss, Misses Revenue Estimates
Salarius (SLRX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.10 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 11.11%. A quarter ago, it was expected that this biotech drug developer would post a loss of $0.06 per share when it actually produced a loss of $0.07, delivering a surprise of -16.67%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.